Shockwave Appoints Keith D. Dawkins M.D. as Chief Medical Officer
SANTA CLARA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Keith D. Dawkins, M.D. as Chief Medical Officer.
“Given the challenges associated with treating calcium throughout the cardiovascular system, joining Shockwave and contributing to the development of what will likely become the new standard of care for calcium modification was an attractive opportunity,” said Dr. Dawkins. “The Company has made significant progress in the last year in both technology development and the successful application of IVL to a variety of clinical settings; I believe that the future potential of IVL has yet to be fully realized.”
Prior to Shockwave, Dr. Dawkins served as Global Chief Medical Officer and Executive Vice President to Boston Scientific Corporation, as well as a member of that Company’s Executive Committee from 2012 to 2017. This role followed Dr. Dawkins’ time as Chief Medical Officer to the Boston Scientific Cardiology, Rhythm and Vascular Group from 2010 to 2012. He joined Boston Scientific in 2008 as Senior Vice President and Associate Chief Medical Officer of the cardiovascular business. Earlier in his career, Dr. Dawkins was a practicing interventional cardiologist for more than 20 years in the U.K. He has earned a series of clinical, research and academic distinctions, including a Post-Doctoral Research Fellowship at Stanford University as a Fulbright Scholar. Dr. Dawkins served as President of the British Cardiovascular Intervention Society (BCIS) and held numerous appointments on hospital, regional and national committees, including the National Institute for Health and Clinical Excellence (NICE). He has been an author on more than 750 academic publications and presentations on a variety of cardiac topics.
“Having Keith join Shockwave brings a great depth of experience to the organization,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “His expertise from the physician and industry perspective will offer significant value to both our customers and teams across Shockwave as we continue to expand access to our existing technology and to develop new applications for IVL.”
Dr. Dawkins earned a First Class Honours degree in Pathology at London University and Guy’s Hospital. He trained in cardiology at Oxford and at the Royal Brompton & St. George’s Hospital in London.
Dr. Dawkins will serve Shockwave on a half-time basis as he is also currently serving as the Chief Medical Officer to 4TECH Cardio Inc. and is a Senior Advisor to Conformal Medical, in addition to serving on the Board of Directors for several companies including Avicena, JenaValve and InnovHeart.
About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated by establishing a new standard of care with Intravascular Lithotripsy (IVL). The company’s differentiated and proprietary IVL approach to calcium modification uses sonic pressure waves to safely and effectively fracture problematic calcium throughout the cardiovascular system in a wide and growing number of applications. For more information, visit www.shockwavemedical.com.
Caution Regarding Forward-Looking Statements
This press release may contain forward-looking statements regarding Shockwave’s current expectations. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those described more fully in the section captioned “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Shockwave undertakes no duty to update such information except as required under applicable law.
Debbie Kaster, Gilmartin Group
Source: Shockwave Medical, Inc.